Lecalpin (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells. This inhibition prevents calcium‑induced contraction, leading to vasodilation of peripheral arteries, a fall in systemic vascular resistance, and ultimately a reduction in arterial blood pressure.

The appropriate dose of Lecalpin is determined by the prescribing healthcare professional based on the patient’s clinical condition, blood‑pressure response, and any co‑existing medical factors. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecalpin belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation with a relatively long half‑life, which allows once‑daily dosing. Compared with beta‑blockers or ACE inhibitors, it may cause fewer metabolic effects but can be associated with peripheral edema, a common class‑related side effect.

Lecalpin tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Lecalpin is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious adverse events, though rare, include severe hypotension, myocardial infarction, hepatic dysfunction, and allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience sudden dizziness, chest pain, jaundice, swelling of the face or throat, or any signs of an allergic response.

Lecalpin is contraindicated in individuals with known hypersensitivity to lercanidipine or other dihydropyridine calcium‑channel blockers. It should also be avoided in patients with severe aortic stenosis or uncontrolled heart failure unless a specialist determines that benefits outweigh risks.